nav-left cat-right

HIV immune discovery

A new discovery that explains how the body’s immune system makes a potent antibody that blocks HIV infection may be an important step toward developing a vaccine against the virus.

Scientists from the National Institute of Allergy and Infectious Diseases analyzed data from the results of a clinical trial of the only experimental HIV vaccine to date that’s shown modest success in people. Trial results showed that antibodies that bind to the V1V2 region of HIV’s Envelope protein correlated with lower infection rates among those who were vaccinated.

Many researchers believe that an effective vaccine against HIV would work by eliciting powerful antibodies to a specific conserved site on the virus called V1V2, one of a handful of sites that remains constant on the fast-mutating virus.

Along with investigators from Columbia University, the Centre for the AIDS Programme of Research in South Africa and the National Institute for Communicable Diseases in Johannesburg, the NIAID researchers identified an HIV-infected subject who naturally developed V1V2-directed HIV neutralizing antibodies, named CAP256-VRC26, after several months of infection.